Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Ocular Therapeut (OCUL)

Ocular Therapeut (OCUL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 241,041
  • Shares Outstanding, K 77,010
  • Annual Sales, $ 43,520 K
  • Annual Income, $ -6,550 K
  • 60-Month Beta 1.35
  • Price/Sales 5.40
  • Price/Cash Flow N/A
  • Price/Book 5.08
Trade OCUL with:

Options Overview Details

View History
  • Implied Volatility 115.61% ( +9.04%)
  • Historical Volatility 71.40%
  • IV Percentile 74%
  • IV Rank 46.42%
  • IV High 236.19% on 09/30/22
  • IV Low 11.14% on 03/18/22
  • Put/Call Vol Ratio 0.03
  • Today's Volume 372
  • Volume Avg (30-Day) 241
  • Put/Call OI Ratio 0.29
  • Today's Open Interest 13,863
  • Open Int (30-Day) 14,901

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.26
  • Number of Estimates 4
  • High Estimate -0.20
  • Low Estimate -0.30
  • Prior Year -0.23
  • Growth Rate Est. (year over year) -13.04%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.77 +7.94%
on 11/09/22
3.62 -17.29%
on 11/07/22
-0.51 (-14.57%)
since 11/04/22
3-Month
2.77 +7.94%
on 11/09/22
6.53 -54.18%
on 09/12/22
-2.33 (-43.80%)
since 09/02/22
52-Week
2.77 +7.94%
on 11/09/22
7.39 -59.54%
on 12/09/21
-3.17 (-51.46%)
since 12/03/21

Most Recent Stories

More News
Ocular Therapeutix™ to Participate at Three Upcoming Investor Conferences

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today...

OCUL : 2.99 (-4.47%)
Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates (Revised)

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -30.43% and 18.63%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?...

OCUL : 2.99 (-4.47%)
ALPN : 6.74 (+3.69%)
Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -34.78% and 18.63%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?...

OCUL : 2.99 (-4.47%)
ALPN : 6.74 (+3.69%)
Ocular Therapeutix: Q3 Earnings Snapshot

Ocular Therapeutix: Q3 Earnings Snapshot

OCUL : 2.99 (-4.47%)
Ocular Therapeutix™ Reports Third Quarter 2022 Financial Results and Business Update

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today...

OCUL : 2.99 (-4.47%)
Ocular Therapeutix™ To Report Third Quarter 2022 Financial Results

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today...

OCUL : 2.99 (-4.47%)
Ocular Therapeutix (OCUL) Soars 24.2%: Is Further Upside Left in the Stock?

Ocular Therapeutix (OCUL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near...

OCUL : 2.99 (-4.47%)
COLL : 22.73 (-1.26%)
Ocular (OCUL) Announces Positive Data on Wet AMD Candidate

Ocular (OCUL) interim seven-month data on OTX-TKI from a phase I study for treating wet age-related macular degeneration (wet AMD) shows a favorable safety profile, and stable and sustained visual acuity....

REGN : 755.45 (-1.43%)
BAYRY : 13.9800 (-3.65%)
OCUL : 2.99 (-4.47%)
BOLT : 1.4000 (-3.45%)
Ocular Therapeutix™ Announces Interim 7-month Data from U.S. Phase 1 Clinical Trial of OTX-TKI for the Treatment of Wet AMD

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today...

OCUL : 2.99 (-4.47%)
Ocular Therapeutix™ To Present Data at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today...

OCUL : 2.99 (-4.47%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Ocular Therapeutix, Inc. is a biopharmaceutical company. It is focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. The Company develops and markets eye care products. Ocular...

See More

Key Turning Points

3rd Resistance Point 3.38
2nd Resistance Point 3.26
1st Resistance Point 3.13
Last Price 2.99
1st Support Level 2.88
2nd Support Level 2.76
3rd Support Level 2.63

See More

52-Week High 7.39
Fibonacci 61.8% 5.63
Fibonacci 50% 5.08
Fibonacci 38.2% 4.53
Last Price 2.99
52-Week Low 2.77

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar